Reaction
Blastomycosis reporting signals
As of the last recalculation, Blastomycosis appears in 473 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is TACROLIMUS OINTMENT 0.1% (PRR 122.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tacrolimus Ointment 0.1% | 201 | 122.8 | 123.0 |
| Tacrolimus Extended-Release Capsules | 201 | 122.4 | 122.6 |
| Mycophenilic Acid | 48 | 113.3 | 113.6 |
| Tacrolimus | 209 | 104.4 | 104.5 |
| Amphotericin B | 21 | 77.1 | 77.3 |
| Mycophenolic Acid | 49 | 75.0 | 75.2 |
| Valganciclovir Hydrochloride Powder, | 19 | 71.4 | 71.5 |
| Mycophenolate Mofetil | 138 | 62.7 | 62.8 |
| Mycophenolate Mofetil Hydrochloride | 138 | 62.6 | 62.7 |
| Itraconazole | 16 | 62.4 | 62.4 |
| Basiliximab | 15 | 57.9 | 58.0 |
| Anti-Thymocyte Globulin (Rabbit) | 10 | 55.7 | 55.8 |
| Valganciclovir | 21 | 51.2 | 51.3 |
| Valganciclovir Hydrochloride | 21 | 51.2 | 51.3 |
| Cefepime Hydrochloride | 13 | 36.5 | 36.5 |
| Voriconazole Injection | 17 | 35.7 | 35.7 |
| Cefepime | 11 | 34.5 | 34.6 |
| Sirolimus | 10 | 33.3 | 33.4 |
| Voriconazole | 21 | 31.8 | 31.8 |
| Micafungin Sodium | 5 | 26.2 | 26.2 |
| Benralizumab | 5 | 11.1 | 11.1 |